
Loading, please wait...

Loading, please wait...

Hyperhidrosis is a functional disorder characterized by excessive sweat production beyond physiological needs for thermoregulation. This condition significantly impairs quality of life, affecting physical comfort, psychological well-being, and work productivity. Consequently, effective hyperhidrosis treatment management has become a priority for clinicians addressing patient-centered care. A systematic review of recent literature highlights several evidence-based therapeutic options that offer sustained symptom control.
Topical treatments remain the first-line defense for localized forms of the disorder. For instance, glycopyrronium bromide and aluminum salts provide significant relief for axillary sweating with manageable side effects. However, when patients present with multisite involvement, systemic therapy often becomes necessary. Furthermore, oral oxybutynin has shown strong efficacy in clinical studies, though physicians must monitor for xerostomia and other anticholinergic effects. Similarly, botulinum toxin injections offer a powerful, minimally invasive option for focal cases, providing long-lasting results for those who do not respond to topicals.
Managing this condition requires a nuanced strategy that balances safety and patient preferences. Moreover, combination therapies and flexible treatment sequencing can reduce early reliance on invasive procedures. Surgery, such as local excision or sympathectomy, remains a last-line option for refractory cases. Therefore, a stepwise approach ensures that patients achieve meaningful improvement in quality of life while minimizing risks. Additionally, future research continues to focus on developing selective, well-tolerated therapies to address the psychosocial impact of the disease.
Topical options include aluminum salts and anticholinergics like glycopyrronium bromide or tosylate, which are effective for localized axillary hyperhidrosis.
Clinicians typically consider systemic agents, such as oral oxybutynin, for patients with multisite or generalized hyperhidrosis that does not respond to topical therapy.
No, surgery is generally reserved for severe, refractory cases where conservative pharmacological treatments and botulinum toxin have failed to provide relief.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. The information provided should not be used for diagnosing or treating a health problem or disease. Refer to the latest local and national guidelines for clinical practice.
References
Rossi A et al. ADVANCES IN PHARMACOLOGICAL TREATMENT AND MANAGEMENT OF HYPERHIDROSIS. Expert Opin Pharmacother. 2026 Mar 23. doi: 10.1080/14656566.2026.2642213. PMID: 41871366.
Litchman G, et al. Primary hyperhidrosis: an updated review. PMC. 2025 Jun 16. doi: 10.7573/dic.2025-3-2. PMID: 40575073.
Friedman A. Advances in the Management of Hyperhidrosis. Skin Therapy Lett. 2026 Mar 12. Volume 31, No. 2.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A comprehensive review of the latest evidence-based pharmacological and surgical strategies for managing primary focal and multisite hyperhidrosis....
6 months ago

Following Nigeria's first recorded Ebola case linked to regional travel, the Africa CDC has convened an emergency ministerial summit. This alert underscores critical clinical priorities for healthcare professionals, including differentiating early viral infection from malaria, implementing barrier nursing, and triage.
Today

Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today